Novel GHRH Antagonist MIA-690 Suppressed Human Melanoma Tumor Growth by 70.45% in Mice
Background
Advanced and recurrent malignant melanoma, the most lethal form of skin cancer, presents a significant treatment challenge. Current therapeutic options often struggle with efficacy and resistance, necessitating novel approaches. Recent findings have implicated the growth hormone-releasing hormone (GHRH) receptor (GHRHR) in the pathogenesis of melanoma, suggesting it as a viable therapeutic target. This pathway's involvement in cell growth and proliferation makes its antagonism a promising strategy. This study explores the potential of novel, synthetic GHRH antagonists to directly combat melanoma growth by manipulating key cell cycle regulators like the tumor suppressor protein p27.
Study Design
Researchers investigated the antiproliferative effects of three GHRH antagonists, MIA-602, MIA-606, and MIA-690, on the human melanoma cell line A-375 in vitro using the MTS assay. The most effective compound, MIA-690, was then evaluated in vivo. Nude mice bearing xenografts of A-375 tumor cells were treated with MIA-690 (5 μg/day) for 28 days. The primary endpoints were tumor growth suppression in vivo and cell proliferation inhibition in vitro. Subcellular localization of p27 was analyzed using Western blot and immunofluorescent staining, while cell cycle effects were determined via flow cytometry.
Results
In vitro, MIA-690 inhibited the proliferation of A-375 melanoma cells in a dose-dependent manner, causing a 33% reduction at 10 μM and a 19.2% reduction at 5 μM (both P < 0.05 vs. control). In the in vivo mouse model, daily administration of MIA-690 resulted in a dramatic reduction in the growth of xenografted tumors.
MIA-690 suppressed tumor growth by 70.45% compared to the control group (P < 0.05). Mechanistically,
flow cytometryrevealed that MIA-690 treatment caused a significant decrease in the number of cells in theG2/Mphase of the cell cycle, from 19.7% to 12.9% (P < 0.001).Western blotand immunofluorescence studies confirmed that this cell cycle arrest was triggered by the nuclear accumulation of the tumor suppressor proteinp27, which MIA-690 induced.
Key Findings
- The GHRH antagonist MIA-690 suppressed the growth of human melanoma xenograft tumors in nude mice by 70.45% (P < 0.05).
- In vitro, MIA-690 inhibited A-375 cell proliferation by 33% at a concentration of 10 μM (P < 0.05).
- MIA-690 treatment reduced the percentage of melanoma cells in the G2/M phase of the cell cycle from 19.7% to 12.9% (P < 0.001).
- The compound was shown to trigger the nuclear accumulation of the tumor suppressor protein p27.
Why It Matters
The study demonstrates that antagonizing the GHRH receptor with compounds like MIA-690 is a potent strategy for inhibiting melanoma growth. This is achieved by forcing the tumor suppressor protein p27 back into the cell nucleus, where it can halt uncontrolled cell division. For clinicians and researchers, this opens a new avenue for melanoma treatment, suggesting that GHRH antagonists could be valuable additions to existing therapeutic regimens. The findings strongly support the development of GHRH antagonists as a component of combination therapy, potentially alongside standard chemotherapy agents, to improve outcomes for patients with advanced malignant melanoma. While these are preclinical results from cell and animal models, they provide a strong rationale for advancing these compounds toward clinical trials in humans.
ghrh antagonist
mia-690
mia-602
mia-606
malignant melanoma
cancer
